Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926637 · ClinicalTrials.gov registry record
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
A clinical trial, sponsored by Biogen.
- Terminated
- Registry status
- 3,073
- Enrollment target
NCT03926637 is a clinical trial that was terminated before completion, run by Biogen. The registered enrollment target is 3,073 participants.
The verdict
NCT03926637 was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- 3,073 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
Interventions
- OTHER Multiple Sclerosis Performance Test (MSPT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,073 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2022-12-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926637
The ClinicalTrials.gov registry entry for NCT03926637 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3,073 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multiple Sclerosis Performance Test (MSPT) is the first listed.
NCT03926637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03926637 about?
NCT03926637 is a clinical study titled "Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis". The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
What is the current status of trial NCT03926637?
This trial is currently terminated. The enrollment target is 3,073 participants. The study started on 2019-06-17. Estimated completion is 2022-12-05.
What interventions are being tested in trial NCT03926637?
The interventions under investigation include: Multiple Sclerosis Performance Test (MSPT) (OTHER).
Who is sponsoring clinical trial NCT03926637?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.